GHRP-6
GHRP-6 (Growth Hormone Releasing Peptide-6)
Ghrelin Receptor Agonist for Growth Hormone Stimulation
What is GHRP-6?
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that was among the first compounds developed to pharmacologically stimulate growth hormone (GH) secretion through a mechanism independent of the hypothalamic growth hormone-releasing hormone (GHRH) axis. Originally developed as a research tool for studying GH regulation, GHRP-6 has attracted sustained interest in the fields of anti-aging medicine, body composition research, and recovery protocols due to its ability to produce robust, pulsatile GH release.
The compound works by binding to and activating the ghrelin receptor, formally known as the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is an endogenous gut hormone involved in appetite regulation, energy balance, and GH pulsatility. GHRP-6 mimics ghrelin's action at this receptor, triggering signaling cascades that include phosphatidylinositol turnover, PKC activation, and intracellular calcium mobilization. Critically, this signaling pathway is entirely separate from the one that GHRH uses, which is why combining GHRP-6 with a GHRH analog (such as CJC-1295) produces synergistic effects on GH output rather than simple additive effects.
Beyond growth hormone stimulation, research published in peer-reviewed journals has documented cytoprotective and anti-inflammatory properties for GHRP-6 that appear to be at least partially independent of GH release. These effects have been studied in cardiac, hepatic, and wound-healing models. A clinical safety study in healthy volunteers confirmed that GHRP-6 is well-tolerated, with the most notable acute effect being intense appetite stimulation occurring within 20 to 30 minutes of injection.
GHRP-6 is not approved by the FDA for any clinical use. It is classified as a research compound and is not intended for human therapeutic use outside of controlled research settings.
Research Supply
Source high-purity GHRP-6 for your research
Dosage Guide
Route: Subcutaneous injection, in a fasted state (30-60 minutes before eating or 2+ hours after a meal)
Dosing Schedule
| Period | Dose |
|---|---|
| Entry level | 100 mcg, 1-2x daily (minimal appetite stimulation) |
| Standard research | 100-200 mcg, 2-3x daily |
| High dose | 300 mcg, 2-3x daily (significant hunger) |
| Combined with GHRH analog | 100 mcg GHRP-6 + 100 mcg CJC-1295, 2-3x daily |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 100 mcg | 0.05 mL | 5 units |
| 200 mcg | 0.10 mL | 10 units |
| 300 mcg | 0.15 mL | 15 units |
Cycling Protocol
8-12 weeks
8-12 weeks
Cycling prevents GHS-R1a receptor desensitization and maintains GH pulse responsiveness
Administration Tips
- Inject in a fasted state -- GH release is blunted by elevated blood glucose and circulating fatty acids
- Optimal injection timing windows: upon waking (fasted), pre-workout, and at bedtime
- Inject subcutaneously into the abdominal region, thigh, or deltoid area
- Expect intense hunger within 20-30 minutes of injection -- have a plan for managing appetite
- Research protocols typically run 8-12 weeks followed by a comparable off period to minimize receptor desensitization
- Store reconstituted solution refrigerated and use within 30 days
Risks & Side Effects
Commonly Reported
Serious Risks
Pituitary desensitization
Chronic high-frequency dosing can desensitize the GHS-R1a receptor, diminishing GH response over time. Cycling protocols are recommended to preserve receptor sensitivity.
Insulin resistance exacerbation
GH-mediated antagonism of insulin signaling can worsen pre-existing insulin resistance. Individuals with metabolic syndrome or diabetes should use extreme caution.
Promotion of malignancy
Elevated GH and IGF-1 are mitogenic. Use in individuals with active cancer or a history of malignancy is a serious concern requiring specialist evaluation.
Edema progression
Water retention can progress to clinically significant edema in susceptible individuals, particularly at higher doses.
Contraindications
- Active or history of malignancy (GH and IGF-1 are growth-promoting)
- Diabetic individuals or those with insulin resistance (GH is diabetogenic)
- Pregnancy and breastfeeding
- Active acromegaly or pre-existing elevated GH/IGF-1
- Pediatric use (open growth plates; GH stimulation may cause disproportionate growth)
- Individuals with hypersensitivity to any component of the formulation
Frequently Asked Questions
Related Peptides
Experts Covering GHRP-6
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. GHRP-6 has not been approved by the FDA for any medical condition. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.